miR-496 MTFR2在胰腺癌中的表达及临床意义

doi:10.3969/j.issn.1006-6233.2025.02.014

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1662 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨微小RNA-496(miR-496)、线粒体裂变调节因子2(MTFR2)在胰腺癌组织中的表达情况及其临床价值。方法: 收集2020年4月至2021年4月期间于本院确诊的124例胰腺癌患者为研究对象,获取患者的癌组织及其癌旁组织,根据3年预后将患者分为生存组79例和死亡组45例。采用实时荧光定量PCR法检测各组织中miR-496的表达水平,采用免疫组化法检测组织中MTFR2蛋白表达水平;采用Kaplan-Meier法分析胰腺癌组织miR-496、MTFR2表达水平与患者3年预后的关系;采用Cox比例风险回归模型分析胰腺癌患者3年预后的影响因素。结果: 胰腺癌组织MTFR2蛋白阳性率(70.97%)高于癌旁组织(18.55%),miR-140-5p表达水平(0.64±0.18)低于癌旁组织(1.02±0.24)(χ²/t=68.902、14.105,P<0.05)。 TNM分期Ⅲ+Ⅳ期、组织分化程度低分化、淋巴结转移阳性、远处转移阳性的胰腺癌组织中miR-496低表达患者组(76.74%、82.22%、79.59%、78.12%)比例高于miR-496高表达组(23.26%、17.78%、20.41%、21.88%)(χ²=17.719、27.892、26.858、12.879,P<0.05), MTFR2阳性表达患者组(86.05%、84.44%、83.67%、87.50%)比例高于MTFR2阴性表达组(13.95%、15.56%、16.33%、12.50%)(χ²=7.264、6.226、6.348、5.721,P<0.05)。胰腺癌组织miR-496低表达患者3年生存率(34.92%)低于miR-496高表达患者(93.44%)(χ²=45.908,P<0.05);胰腺癌组织MTFR2阴性表达患者3年生存率(94.33%)高于MTFR2阳性表达患者(51.14%)(χ²=20.726,P<0.05)。单因素及多因素Cox回归分析结果显示,MTFR2是胰腺癌患者3年内死亡的独立危险因素,miR-496是胰腺癌患者3年内死亡的保护因素(P<0.05)。结论: miR-496、MTFR2表达与胰腺癌疾病进展密切相关,有望成为预后评估标志物。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：胰腺癌, 微小RNA-496, MTFR2, 临床病理特征, 预后

Abstract：Objective: To investigate the expression of microRNA-496 (miR-496) and mitochondrial fission regulator 2 (MTFR2) in pancreatic cancer tissues and their clinical significance. Methods: A total of 124 patients with pancreatic cancer diagnosed at our hospital between April 2020 and April 2021 were included in the study. Cancerous and adjacent tissues were collected from these patients. Based on a 3-year follow-up, the patients were divided into a survival group (79 cases) and a death group (45 cases). The expression levels of miR-496 in different tissues were detected using real-time quantitative PCR, and the expression levels of MTFR2 protein in tissues were detected using immunohistochemistry. Kaplan-Meier analysis was used to analyze the relationship between miR-496 and MTFR2 expression and the 3-year prognosis of pancreatic cancer patients. Cox proportional hazards regression model was used to analyze the factors influencing the 3-year prognosis of pancreatic cancer patients. Results: The positive rate of MTFR2 protein expression in pancreatic cancer tissues (70.97%) was higher than that in adjacent tissues (18.55%), while the expression level of miR-496 (0.64±0.18) in cancer tissues was lower than that in adjacent tissues (1.02±0.24) (χ²/t = 68.902, 14.105, P < 0.05). In pancreatic cancer tissues with TNM stage III + IV, low differentiation, lymph node metastasis, and distant metastasis, the proportion of patients with low miR-496 expression (76.74%, 82.22%, 79.59%, 78.12%) was higher than those with high miR-496 expression (23.26%, 17.78%, 20.41%, 21.88%) (χ² = 17.719, 27.892, 26.858, 12.879, P < 0.05). The proportion of patients with positive MTFR2 expression (86.05%, 84.44%, 83.67%, 87.50%) was higher than those with negative MTFR2 expression (13.95%, 15.56%, 16.33%, 12.50%) (χ² = 7.264, 6.226, 6.348, 5.721, P < 0.05). The 3-year survival rate of patients with low miR-496 expression in pancreatic cancer tissues (34.92%) was significantly lower than that of patients with high miR-496 expression (93.44%) (χ² = 45.908, P < 0.05). The 3-year survival rate of patients with negative MTFR2 expression in pancreatic cancer tissues (94.33%) was significantly higher than that of patients with positive MTFR2 expression (51.14%) (χ² = 20.726, P < 0.05). Univariate and multivariate Cox regression analyses showed that MTFR2 was an independent risk factor for 3-year mortality in pancreatic cancer patients, while miR-496 was a protective factor for 3-year mortality (P < 0.05). Conclusion: The expression of miR-496 and MTFR2 is closely associated with the progression of pancreatic cancer and may serve as potential prognostic biomarkers.

Key words： Pancreatic cancer MicroRNA-496 MTFR2 Clinical pathological features Prognosis

基金资助:河北省医学科学研究重点课题,(编号:20191475)

引用本文:

李昕, 冯瑾, 关兴, 杜媚娟, 孟宁, 张玉斌. miR-496 MTFR2在胰腺癌中的表达及临床意义[J]. 河北医学, 2025, 31(2): 258-264.
LI Xin, FENG Jin, GUAN Xing, et al. Expression and Clinical Significance of miR-496 and MTFR2 in Pancreatic Cancer. HeBei Med, 2025, 31(2): 258-264.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2025.02.014 或 http://www.hbyxzzs.cn/CN/Y2025/V31/I2/258

[1] Jiang S,Fagman J B,Ma Y,et al.A comprehensive review of pancreatic cancer and its therapeutic challenges[J].Aging (Albany NY),2022,14(18):7635-7649.
[2] Hwang W L,Jagadeesh K A,Guo J A,et al.Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment[J].Nat Genet,2022,54(8):1178-1191.
[3] Halbrook CJ,Lyssiotis C A,Pasca Di Magliano M,et al.Pancreatic cancer: advances and challenges[J].Cell,2023,186(8):1729-1754.
[4] Huang C,Liu J,He L,et al.The long noncoding RNA noncoding RNA activated by DNA damage (NORAD)-microRNA-496-Interleukin-33 axis affects carcinoma-associated fibroblasts-mediated gastric cancer development[J].Bioengineered,2021,12(2):11738-11755.
[5] 付宗立,巨宇叶,胡进静,等.MTFR2在肝癌组织中表达及临床意义的生物信息学分析[J].现代肿瘤医学,2022,30(9):1628-1633.
[6] Wang H,Yan B,Zhang P,et al.MiR-496 promotes migration and epithelial-mesenchymal transition by targeting RASSF6 in colorectal cancer[J].Cell Physiol,2020,235(2):1469-1479.
[7] Dou D,Yang S,Lin Y,et al.An eight-miRNA signature expression-based risk scoring system for prediction of survival in pancreatic adenocarcinoma[J].Cancer Biomark,2018,23(1):79-93.
[8] 中国医师协会肿瘤医师分会,中国医疗保健国际交流促进会胰腺疾病专家委员会,中国医药教育协会腹部肿瘤专家委员会.中国胰腺癌多学科综合治疗模式专家共识(2020版)[J].临床肝胆病杂志,2020,36(9):1947-1951.
[9] Cai J,Chen H,Lu M,et al.Advances in the epidemiology of pancreatic cancer: Trends,risk factors,screening,and prognosis[J].Cancer Lett,2021,520(1):1-11.
[10] 胡春东,王兢,郑立平,等.血浆D-二聚体与胰腺癌患者临床病理特征及预后的相关性[J].肝胆胰外科杂志,2022,34(4):210-213.
[11] Sohrabi E,Rezaie E,Heiat M,et al.An integrated data analysis of mRNA,miRNA and signaling pathways in pancreatic cancer[J].Biochem Genet,2021,59(5):1326-1358.
[12] Fu Y,Liu K,Zhao L,et al.Circular RNA Ubiquitin-associated Protein 2 silencing suppresses bladder cancer progression by downregulating DNA topoisomerase 2-alpha through sponging miR-496[J].Eur Urol Open Sci,2023,50(1):31-42.
[13] Yin H,Hu J,Ye Z,et al.Serum long noncoding RNA NNTAS1 protected by exosome is a potential biomarker and functions as an oncogene via the miR-496/RAP2C axis in colorectal cancer[J].Mol Med Rep,2021,24(2):585-613.
[14] Lian Z,Pang P,Zhu Y,et al.Prognostic value and potential mechanism of MTFR2 in lung adenocarcinoma[J].Front Oncol,2022,12(1):1-27.
[15] Huang Q Q,Han Y,Shen E,et al.MTFR2 shapes a barrier of immune microenvironment in hepatocellular carcinoma[J].iScience,2022,26(1):1-13.